Menu

Investor & Media information

You are here

  1. Home
  2. Media and investors
  3. Investor & Media information

MorphoSys is strictly committed to the principle of fair disclosure. One of the most important foundations of our corporate communication is to inform all stakeholders simultaneously and comprehensively about the situation of the Company. We pay great attention to transparent and timely communication.

Corporate media releases

Date
Title

2018

  1. 21/10/2018
    MorphoSys's Licensing Partner GSK has Reported Data on GSK3196165 from Phase 2 Study in Rheumatoid Arthritis to be Presented at the ACR Conference
  2. 19/10/2018
    MorphoSys's Licensee Janssen has Reported That New Tremfya(R) (Guselkumab) 3-Year Data Shows Stably Maintained Rates of Skin Clearance in Patients with Moderate to Severe Plaque Psoriasis
  3. 25/09/2018
    MorphoSys Announces its Licensee Janssen has Initiated a Phase 3 Trial (PROTOSTAR) to Evaluate Guselkumab in Pediatric Psoriasis Patients
  4. 17/09/2018
    MorphoSys and LEO Pharma Expand Strategic Alliance to Develop Peptide-derived Therapeutics
  5. 13/09/2018
    MorphoSys and Galapagos Announce Start of a Phase 1 Subcutaneous Bridging Study with MOR106
  6. 13/09/2018
    MorphoSys Announces That its Licensee Janssen has Reported That Tremfya(R) Improves Long-Term Patient-Reported Outcomes in Patients with Moderate to Severe Plaque Psoriasis
  7. 12/09/2018
    MorphoSys and Galapagos Announce U.S. Antitrust Clearance for Global License Agreement for MOR106 with Pharma Partner
  8. 06/09/2018
    MorphoSys AG to be listed in MDAX
  9. 08/08/2018
    MorphoSys and I-Mab Biopharma Announce China IND Submission of TJ202/MOR202
  10. 01/08/2018
    MorphoSys AG Reports Second Quarter 2018 Financial Results

Pages

Order form for publications and reports

Ad-hoc releases

Sorry, but there are no ad-hoc releases available for the selected year.

Pages

Presentations
and conferences

Wednesday, June 12, 2019
Presentation: Goldman Sachs 40th Annual Global Healthcare Conference

Dr. Simon Moroney presented the Company at the Goldman Sachs 40th Annual Global Healthcare Conference in Los Angeles, CA, U.S., on Wednesday, June 12, 2019.

DocumentFile info
Company Update2.17 MB

Archive

Date
Title
MP3

2019

  1. 06/12/2019

    Presentation: Goldman Sachs 40th Annual Global Healthcare Conference

  2. 06/06/2019

    Presentation: dbAccess

  3. 06/05/2019

    Webcast: Jefferies Healthcare Conference

  4. 05/20/2019

    Conference call: Q&A session on the headline data of tafasitamab (MOR208)

  5. 05/08/2019

    Conference Call and Webcast: Q1 2019 Financial Results

  6. 04/26/2019

    Presentation: Class of 2018 Biotech IPOs Investor Day

  7. 04/16/2019

    Presentation: Kempen Life Sciences Conference

  8. 03/14/2019

    Year-End 2018 Conference Call and Webcast

  9. 02/28/2019

    Webcast: 8th Annual Leerink Partners Global Healthcare Conference

  10. 01/21/2019

    Presentation: Kepler Chevreux German Corporate Conference

  11. 01/14/2019

    Presentation: Commerzbank German Investment Seminar 2019

  12. 01/09/2019

    Webcast: JPMorgan Annual Healthcare Conference 2019

2018

  1. 12/06/2018

    Presentation: Berenberg European Conference 2018

  2. 12/05/2018

    Webcast: Investor & Analyst Event

  3. 11/28/2018

    Presentation: Piper Jaffray Annual Healthcare Conference

  4. 11/26/2018

    Presentation: German Eigenkapitalforum

  5. 11/22/2018

    Presentation: Bryan Garnier 6th Annual Healthcare Conference

  6. 11/06/2018

    Conference Call and Webcast: Q3 2018 Financial Results

  7. 10/03/2018

    Webcast: Leerink Partners Roundtable Series: Rare Disease & Oncology

  8. 09/25/2018

    Presentation: Berenberg and Goldman Sachs Seventh German Corporate Conference

  9. 09/24/2018

    Presentation: Baader Investment Conference

  10. 09/07/2018

    Presentation: Goldman Sachs Eighth Annual Biotech Symposium

  11. 08/28/2018

    Presentation: Commerzbank Sector Conference

  12. 08/02/2018

    Conference Call and Webcast: Q2 2018 Financial Results

  13. 06/20/2018

    Webcast: JMP Securities Life Sciences Conference

Pages

Pictures

Management Board

Dr. Simon E. Moroney

Chief Executive Officer,
MorphoSys AG

Jens Holstein

Chief Financial Officer,
MorphoSys AG

Dr. Malte Peters

Chief Development Officer,
MorphoSys AG

Dr. Markus Enzelberger

Chief Scientific Officer,
MorphoSys AG

Technology

Ylanthia

Ylanthia technology

Slonomics

Slonomics technology

HuCAL

HuCAL antibody library

HuCAL

Scientist working with the HuCAL library

Lab shots

Antibody purification

Scientist in protein chemistry lab

Daily work

MorphoSys scientist working in laboratory

Scientist with petri dishes

MorphoSys scientist handling petri dishes

Cell culture experiment

MorphoSys scientist in cell culture lab

Miscellaneous

MorphoSys Building Planegg

View of the Building of MorphoSys in Planegg/Munich, Germany

MorphoSys Building Planegg

Entrance of the Building of MorphoSys in Planegg/Munich, Germany

MorphoSys Logo
MorphoSys Footage Video

Copyright notice: The photos provided for download on this website can be used free of charge in the context of editorial reporting with the indication of the photo credit "©MorphoSys AG".